

DNA Script partners with Premas Life Sciences for 'Same-day Enzymatic DNA Synthesis'

05 May 2022 | News

This partnership represents an important step in DNA Script's global commercial expansion

French firm DNA Script has reached a distribution agreement with Premas Life Sciences to expand DNA Script's footprint and provide sales and support for the SYNTAX System DNA printer in labs in India.

APAC is experiencing significant genomic research growth, spurring increased demand for synthetic biology tools, including DNA Script's SYNTAX System. As the world's first commercial benchtop enzymatic DNA printer, the SYNTAX System gives labs complete control over their oligo production, alleviating the need to wait for deliveries from third-party DNA service providers and dramatically accelerating their research.

Dr. Debjani Saha, Assistant General Manager-Marketing at Premas Life Sciences, commented, "With the scope for synthesized oligos in therapeutic applications and the growing focus on personalized medicine, we anticipate a keen interest in SYNTAX. A big advantage of this benchtop product is that you can quickly print customized oligos in-house without being dependent on centralized services providers."

The SYNTAX System printer is the only commercial DNA manufacturing technology that utilizes the power of Enzymatic DNA Synthesis (EDS), which produces synthetic DNA without the toxic reagents and hazardous waste associated with older DNA printing methods. Companies can now iterate in a matter of hours by printing ready-to-use oligos in-house instead of waiting days for outsourced service providers to deliver the DNA needed.